Treatment of menopausal symptoms: What shall we do now?

Lancet

Volumn 366, Issue 9483, 2005, Pages 409-421

  Hickey, Martha ^a   Davis, Susan R ^b   Sturdee, David W ^c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c SOLIHULL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL SUCCINATE; ANDROGEN; BELLADONNA ALKALOID; BISPHOSPHONIC ACID DERIVATIVE; CIMICIFUGA RACEMOSA EXTRACT; CLONIDINE; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ERGOTAMINE; ESTRADIOL; ESTRIOL; ESTROGEN; ESTRONE; ESTRONE SULFATE; GESTAGEN; MEDROXYPROGESTERONE ACETATE; MEGESTROL; METHYLDOPA; PHENOBARBITAL; PRASTERONE SULFATE; PREGNENOLONE; PRIMROSE OIL; PROGESTERONE; SEROTONIN UPTAKE INHIBITOR; SEX HORMONE; TAMOXIFEN; TESTOSTERONE; TIBOLONE; UNINDEXED DRUG; VERALIPRIDE;

ACUPUNCTURE; ANGELICA SINENSIS; ATROPHY; BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; COLORECTAL CANCER; DEMENTIA; DIZZINESS; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SAFETY; ENDOMETRIUM CANCER; FRACTURE; HEADACHE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; LIBIDO DISORDER; LIFESTYLE; MENOPAUSAL SYNDROME; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SLEEP DISORDER; STROKE; VAGINAL DRYNESS; VENOUS THROMBOEMBOLISM; YAM;

EID: 23044463639     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)66519-1     Document Type: Review

References (154)

1. F Kronenberg Hot flashes: epidemiology and physiology Ann N Y Acad Sci 592 1990 52 86 discussion 123-33
2. WHO Technical report series: menopause 7 1966 236 242
3. DW Sturdee, KA Wilson, E Pipili, AD Crocker Physiological aspects of menopausal hot flush BMJ 2 1978 79 80
4. R Freedman Physiology of hot flushes Am J Human Biol 13 2001 453 464
5. TD Shanafelt, DL Barton, AA Adjei, CL Loprinzi Pathophysiology and treatment of hot flashes Mayo Clin Proc 77 2002 1207 1218
6. V Stearns, L Ullmer, JF Lopez, Y Smith, C Issacs, DF Hayes Hot flushes Lancet 360 2002 1851 1861
7. CC Slater, HN Hodis, WJ Mack, D Shoupe, RJ Paulson, FZ Stanczyk Markedly elevated levels of estrone sulfate after long-term oral, but not transdermal, administration of estradiol in postmenopausal women Menopause 8 2001 200 203
8. LE Nachtigall, U Raju, S Banerjee, L Wan, M Levitz Serum estradiol-binding profiles in postmenopausal women undergoing three common estrogen replacement therapies: associations with sex hormone-binding globulin, estradiol, and estrone levels Menopause 7 2000 243 250
9. JR Pasqualini, G Chetrite, C Blacker Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients J Clin Endocrinol Metab 81 1996 1460 1464
10. J Slowinska-Srzednicka, S Zgliczynski, W Jeske Transdermal 17 beta-estradiol combined with oral progestogen increases plasma levels of insulin-like growth factor-I in postmenopausal women J Endocrinol Invest 15 1992 533 538
11. LA Boothby, PL Doering, S Kipersztok Bioidentical hormone therapy: a review Menopause 11 2004 356 367
12. AH MacLennan, S Lester, V Moore Oral estrogen replacement therapy versus placebo for hot flushes Cochrane Database Syst Rev 1 2002 CD002978
13. E Simpson, G Rubin, C Clyne The role of local estrogen biosynthesis in males and females Trends Endocrinol Metab 11 2000 184 188
14. GA Bachmann The clinical platform for the 17beta-estradiol vaginal releasing ring Am J Obstet Gynecol 178 1998 S257 S260
15. L Cardozo, G Bachmann, D McClish, D Fonda, L Birgerson Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee Obstet Gynecol 92 1998 722 727
16. V Baker Alternatives to oral oestrogen replacement: transdermal patches, percutaneous gels, vaginal creams and rings, implants, other methods of delivery Obstet Gynecol Clin North Am 21 1994 271 297
17. JS Brown, E Vittinghoff, AM Kanaya Urinary tract infections in postmenopausal women: effect of hormone therapy and risk factors Obstet Gynecol 98 2001 1045 1052
18. F Grodstein, K Lifford, NM Resnick, GC Curhan Postmenopausal hormone therapy and risk of developing urinary incontinence Obstet Gynecol 103 2004 254 260
19. M Bygdeman, ML Swahn Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women Maturitas 23 1996 259 263
20. LE Nachtigall Comparative study: replens versus local estrogen in menopausal women Fertil Steril 61 1994 178 180
21. I Schiff, D Tulchinsky, D Cramer, KJ Ryan Oral medroxyprogesterone in the treatment of postmenopausal symptoms JAMA 244 1980 1443 1445
22. K Aslaksen, B Frankendal Effect of oral medroxyprogesterone acetate on menopausal symptoms in patients with endometrial carcinoma Acta Obstet Gynecol Scand 61 1982 423 428
23. M Paterson A randomized double-blind cross-over trial into the effect of norethisterone on climacteric symptoms and biochemical profiles BJOG 89 1982 464 472
24. JC Morrison, DC Martin, RA Blair The use of medroxyprogesterone acetate for relief of climacteric symptoms Am J Obstet Gynecol 138 1980 99 104
25. E Farish, JF Barnes, F O'Donoghue, CD Fletcher, K Ekevall, DM Hart The role of megestrol acetate as an alternative to conventional hormone replacement therapy Climacteric 3 2000 125 134
26. L Dennerstein, GD Burrows, G Hyman, C Wood Menopausal hot flushes: a double blind comparison of placebo, ethinyl oestradiol and norgestrel BJOG 85 1978 852 856
27. A Schindler Differential effects of progestins on hemostasis Maturitas 46 suppl 1 2003 S31 S37
28. SA Khan, JE Pace, ML Cox, DW Gau, SA Cox, HM Hodkinson Climacteric symptoms in healthy middle-aged women Br J Clin Pract 48 1994 240 242
29. L Dennerstein, JR Guthrie, M Clark, P Lehert, VW Henderson A population-based study of depressed mood in the middle-aged, Australian-born women Menopause 11 2004 563 568
30. Writing Group for the Consensus Panel Advice to medical practitioners regarding the use of postmenopausal hormone therapy. Royal Australian and New Zealand College of Obstetricians and Gynaecologists, 2004 http://www.ranzcog. edu.au/media/pdfs/HTAdviceStatement12th%20Aug.pdf (accessed March 8, 2005)
31. JE Rossouw, GL Anderson, RL Prentice Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial JAMA 288 2002 321 333
32. GL Anderson, M Limacher, AR Assaf Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial JAMA 291 2004 1701 1712
33. DP Kiel, DT Felson, JJ Anderson, PW Wilson, MA Moskowitz Hip fracture and the use of estrogens in postmenopausal women: the Framingham Study N Engl J Med 317 1987 1169 1174
34. JA Cauley, DG Seeley, K Ensrud, B Ettinger, D Black, SR Cummings Estrogen replacement therapy and fractures in older women: study of Osteoporotic Fractures Research Group Ann Intern Med 122 1995 9 16
35. JA Kanis Diagnosis of osteoporosis Osteoporosis Int 7 suppl 3 1997 S108 S116
36. KM Prestwood, AM Kenny, A Kleppinger, M Kulldorff Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial JAMA 290 2003 1042 1048
37. SR Cummings, DM Black, SM Rubin Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women Arch Intern Med 149 1989 2445 2448
38. DT Felson, Y Zhang, MT Hannan, DP Kiel, PW Wilson, JJ Anderson The effect of postmenopausal estrogen therapy on bone density in elderly women N Engl J Med 329 1993 1141 1146
39. Y Bagger, L Tanko, Pea Alexanderson Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic factures: the PERF study Bone 34 2004 728 735
40. Critchley H, Gebbie A, Beral V. Menopause and hormone replacement. Proceedings of 47th RCOG Study Group, 2004.
41. H Andrews, B Christie, N Colledge, S Gallacher, A Glasier, J MacDonald Consensus Statement J R Coll Physicians Edinb 34 suppl 13 2004 2 3
42. SR Cummings, DM Black, DE Thompson Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial JAMA 280 1998 2077 2082
43. F Grodstein, ME Martinez, EA Platz Postmenopausal hormone use and risk for colorectal cancer and adenoma Ann Intern Med 128 1998 705 712
44. EE Calle, HL Miracle-McMahill, MJ Thun, CW Heath Jr Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women J Natl Cancer Inst 87 1995 517 523
45. GA Colditz, SE Hankinson, DJ Hunter The use of estrogens and progestins and the risk of breast cancer in postmenopausal women N Engl J Med 332 1995 1589 1593
46. RK Ross, A Paganini-Hill, PC Wan, MC Pike Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin J Natl Cancer Inst 92 2000 328 332
47. C Schairer, J Lubin, R Troisi, S Sturgeon, L Brinton, R Hoover Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk JAMA 283 2000 485 491
48. V Beral Breast cancer and hormone-replacement therapy in the Million Women Study Lancet 362 2003 419 427
49. R Warren Hormones and mammographic breast density Maturitas 49 2004 67 78
50. E Banks, G Reeves, V Beral Impact of use of hormone replacement therapy on false positive recall in the NHS breast screening programme: results from the Million Women Study BMJ 328 2004 1291 1292
51. F Naftolin, H Schneider, D Sturdee Guidelines for the hormone treatment of women in the menopausal transition and beyond: position statement by the executive committee of the International Menopause Society Climacteric 7 2004 333 337
52. A Lethaby, J Suckling, D Barlow, CM Farquhar, RG Jepson, H Roberts Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding Cochrane Database Syst Rev 3 2004 CD000402
53. D Archer, J Gallagher, M Gass, MM Gelfand, VW Henderson, HN Hodis Recommendations for estrogen and progestogen use in peri-and postmenopausal women: October 2004 position statement of the North American Menopause Society North Am Menopause Soc 11 2004 589 600
54. EM Durna, BG Wren, GZ Heller, LR Leader, P Sjoblom, JA Eden Hormone replacement therapy after a diagnosis of breast cancer: cancer recurrence and mortality Med J Aust 177 2002 347 351
55. L Holmberg, H Anderson, H Steering HABITS (hormonal replacement therapy after breast cancer: is it safe?), a randomised comparison: trial stopped Lancet 363 2004 453 455
56. N Biglia, M Cozzarella, F Cacciari Menopause after breast cancer: a survey on breast cancer survivors Maturitas 45 2003 29 38
57. D Hoda, DG Perez, CL Loprinzi Hot flashes in breast cancer survivors Breast J 9 2003 431 438
58. SM Hyder, C Chiappetta, GM Stancel Pharmacological and endogenous progestins induce vascular endothelial growth factor expression in human breast cancer cells Int J Cancer 92 2001 469 473
59. BE Henderson, JT Casagrande, MC Pike, T Mack, I Rosario, A Duke The epidemiology of endometrial cancer in young women Br J Cancer 47 1983 749 756
60. R Horwitz, AR Feinstein Alternative analytic methods for case control studies of oestrogens and endometrial cancer N Engl J Med 299 1978 1089 1094
61. CMF Antunes, PD Stolley, MB Rosenstein Endometrial cancer and oestrogen use: report of a large case control study N Engl J Med 300 1979 9 13
62. RR Paganini-Hill, BE Henderson Endometrial cancer and patterns of use of oestrogen replacement therapy: a cohort study Br J Cancer 59 1989 445 447
63. PK Green, NS Weiss, B McKnight, LF Voigt, SA Beresford Risk of endometrial cancer following cessation of menopausal hormone use Cancer Causes Control 7 1996 575 580
64. JAAWNS Beresford, LF Voigt, B McKnight Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestogen therapy in postmenopausal women Lancet 349 1997 458 461
65. E Weiderpass, HO Adami, JA Baron Risk of endometrial cancer following estrogen replacement with and without progestins J Natl Cancer Inst 91 1999 1131 1137
66. K Bjarnason, A Cerin, R Lindgren, T Weber Adverse endometrial effects during long cycle hormone replacement therapy Maturitas 32 1999 161 170
67. E Pukkala, A Tulenheimo-Silfvast, A Leminem Incidence of cancer among women using long versus monthly cycle HRT Finland 1994-1997 Cancer Causes Control 12 2001 111 115
68. M Wells, DW Sturdee, DH Barlow Effect on endometrium of long term treatment with continuous combined estrogen/progestogen replacement therapy; follow up study BMJ 325 2002 239 242
69. F Riphagen Intrauterine application of progestins in hormone replacement therapy Climacteric 3 2000 199 211
70. DW Sturdee, ML Rantala, JC Colau, HP Zahradnik, FE Riphagen The acceptability of a small intrauterine progestogen-releasing system for continuous combined hormone therapy in early postmenopausal women Climacteric 8 2004 404 411
71. T Raudaskoski, J Tapanainen, E Tomas Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response BJOG 109 2002 136 144
72. V Beral, D Bull, G Reeves Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study Lancet 365 2005 1543 1551
73. MP Warren A comparative review of the risks and benefits of hormone replacement therapy regimens Am J Obstet Gynecol 190 2004 1141 1167
74. D Grady, NK Wenger, D Herrington Postmenopausal hormone therapy increases risk for venous thromboembolic disease: the Heart and Estrogen/progestin Replacement Study Ann Intern Med 132 2000 689 696
75. M Cushman, LH Kuller, R Prentice Estrogen plus progestin and risk of venous thrombosis JAMA 292 2004 1573 1580
76. MP Gomes, SR Deitcher Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review Arch Intern Med 164 2004 1965 1976
77. GD Lowe, MN Upton, A Rumley, A McConnachie, DS O'Reilly, GC Watt Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein: a cross-sectional population survey Thromb Haemost 86 2001 550 556
78. PY Scarabin, E Oger, G Plu-Bureau Estrogen, Group THRS Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk Lancet 362 2003 428 432
79. HD Nelson, LL Humphrey, P Nygren, SM Teutsch, JD Allan Postmenopausal hormone replacement therapy: scientific review JAMA 288 2002 872 881
80. RN Lemaitre, SR Heckbert, BM Psaty, NL Smith, RC Kaplan, WT Longstreth Jr Hormone replacement therapy and associated risk of stroke in postmenopausal women Arch Intern Med 162 2002 1954 1960
81. MS Post, MJ van der Mooren, WM van Baal Effects of low-dose oral and transdermal estrogen replacement therapy on hemostatic factors in healthy postmenopausal women: a randomized placebo-controlled study Am J Obstet Gynecol 189 2003 1221 1227
82. F Grodstein, JE Manson, GA Colditz, WC Willett, FE Speizer, MJ Stampfer A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease Ann Intern Med 133 2000 933 941
83. D Grady, SM Rubin, DB Petitti Hormone therapy to prevent disease and prolong life in postmenopausal women Ann Intern Med 117 1992 1016 1037
84. V Beral, E Banks, G Reeves Evidence from randomised trials on the long-term effects of hormone replacement therapy Lancet 360 2002 942 944
85. S Hulley, D Grady, T Bush Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women JAMA 280 1998 605 613
86. CM Viscoli, LM Brass, WN Kernan, PM Sarrel, S Suissa, RI Horwitz A clinical trial of estrogen-replacement therapy after ischemic stroke N Engl J Med 345 2001 1243 1249
87. SC Clarke, J Kelleher, H Lloyd-Jones, M Slack, PM Schofiel A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study BJOG 109 2002 1056 1062
88. N Cherry, K Gilmour, P Hannaford Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial Lancet 360 2002 2001 2008
89. F Naftolin, HS Taylor, R Karas The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition Fertil Steril 81 2004 1498 1501
90. JE Manson, J Hsia, KC Johnson Estrogen plus progestin and the risk of coronary heart disease N Engl J Med 349 2003 523 534
91. E Lokkegaard, AT Pedersen, P Laursen, IP Loft, S Larsen, T Jorgensen The influence of hormone replacement therapy on the aging-related change in cognitive performance: analysis based on a Danish cohort study Maturitas 42 2002 209 218
92. MC Carlson, PP Zandi, BL Plassman Hormone replacement therapy and reduced cognitive decline in older women: the Cache County Study Neurology 57 2001 2210 2216
93. WL McBee, ME Dailey, E Dugan, SA Shumaker Hormone replacement therapy and other potential treatments for dementias Endocrinol Metab Clin North Am 26 1997 329 345
94. E Le Blanc, B Janowsky, H Chan Nelson HRT and cognition: systematic review and meta-analysis N Engl J Med 285 2001 1489 1499
95. SA Shumaker, C Legault, L Kuller Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study JAMA 291 2004 2947 2958
96. MA Espeland, SR Rapp, SA Shumaker Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study JAMA 291 2004 2959 2968
97. SA Shumaker, C Legault, SR Rapp Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: a randomized controlled trial JAMA 289 2003 2651 2662
98. RA Mulnard, CW Cotman, C Kawas Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial: Alzheimer's Disease Cooperative Study JAMA 283 2000 1007 1015
99. MS Burkhardt, JK Foster, SM Laws Oestrogen replacement therapy may improve memory functioning in the absence of APOE epsilon4 J Alzheimers Dis 6 2004 221 228
100. B Lawton, S Rose, D McLeod, A Dowell Changes in use of hormone replacement therapy after the report from the Women's Health Initiative: cross sectional survey of users BMJ 327 2003 845 846
101. D Grady, B Ettinger, AN Tosteson, A Pressman, JL Macer Predictors of difficulty when discontinuing postmenopausal hormone therapy Obstet Gynecol 102 2003 1233 1239
102. S Haskell After the Women's Health Initiative: postmenopausal women's experiences with discontinuing oestrogen replacement therapy J Women's Health 13 2004 438 442
103. M Hammar, S Christau, J Nathorst-Boos, T Rud, K Garre A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms BJOG 105 1998 904 911
104. BM Landgren, HJ Bennink, FA Helmond, S Engelen Dose-response analysis of effects of tibolone on climacteric symptoms BJOG 109 2002 1109 1114
105. D Bruce, J Robinson, J Rymer Long-term effects of tibolone on the endometrium as assessed by bleeding episodes, transvaginal scan and endometrial biopsy Climacteric 7 2004 261 266
106. MH Milner, MM Sinnott, TM Cooke, A Kelly, T McGill, RF Harrison A 2-year study of lipid and lipoprotein changes in postmenopausal women with tibolone and estrogen-progestin Obstet Gynecol 87 1996 593 599
107. A Gompel, M Siromachkova, A Lombet, HJ Kloosterboer, W Rostene Tibolone actions on normal and breast cancer cells Eur J Cancer 36 suppl 4 2000 S76 S77
108. S Palomba, C Di Carlo, M Morelli Effect of tibolone on breast symptoms resulting from postmenopausal hormone replacement therapy Maturitas 45 2003 267 273
109. B Zumoff, GW Strain, LK Miller, W Rosner Twenty-four-hour mean plasma testosterone concentration declines with age in normal premenopausal women J Clin Endocrinol Metab 80 1995 1429 1430
110. HG Burger, EC Dudley, J Cui, L Dennerstein, JL Hopper A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition J Clin Endocrinol Metab 85 2000 2832 2838
111. GA Laughlin, E Barrett-Connor, D Kritz-Silverstein, D von Muhlen Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: the Rancho Bernardo Study J Clin Endocrinol Metab 85 2000 645 651
112. SR Davis, P McCloud, BJ Strauss, H Burger Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality Maturitas 21 1995 227 236
113. JL Shifren, GD Braunstein, JA Simon Transdermal testosterone treatment in women with impaired sexual function after oophorectomy N Engl J Med 343 2000 682 688
114. R Lobo, RC Rosen, H-M Yang, B Bock, R Van der Hoop Comparative effects of oral esterified estrogens with and without methyl testosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire Fertil Steril 79 2003 1341 1352
115. US FDA Withdrawal of guidance on estrogen and estrogen/progestin- containing drug products http://www.fda.gov/cder/guidance/old054fn.pdf (accessed Feb 17, 2005)
116. C Bolego, A Poli, A Cignarella, R Paoletti Phytoestrogens: pharmacological and therapeutic perspectives Curr Drug Targets 4 2003 77 87
117. SR Davis, FS Dalais, ER Simpson, AL Murkies Phytoestrogens in health and disease Recent Prog Horm Res 54 1999 185 210
118. ED Faure, P Chantre, P Mares Effects of a standardized soy extract on hot flushes: a multicenter, double-blind, randomized, placebo-controlled study Menopause 9 2002 329 334
119. PH van de Weijer, R Barentsen Isoflavones from red clover (Promensil) significantly reduce menopausal hot flush symptoms compared with placebo Maturitas 42 2002 187 193
120. A Crisafulli, H Marini, A Bitto Effects of genistein on hot flushes in early postmenopausal women: a randomized, double-blind EPT- and placebo-controlled study Menopause 11 2004 400 404
121. JA Tice, B Ettinger, K Ensrud, R Wallace, T Blackwell, SR Cummings Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study - a randomized controlled trial JAMA 290 2003 207 214
122. E Krebs, K Ensrud, R Macdonald, T Wilt Phytoestrogens for treatment of menopausal symptons; a systematic review Obstet Gynecol 104 2004 824 836
123. C Atkinson, RM Warren, E Sala Red-clover-derived isoflavones and mammographic breast density: a double-blind, randomized, placebo-controlled trial Breast Cancer Research 6 2004 2170 2179
124. V Unfer, ML Casini, L Costabile, M Mignosa, S Gerli, GC Di Renzo Endometrial effects of long-term treatment with phytoestrogens: a randomized, double-blind, placebo-controlled study Fertil Steril 82 2004 145 148
125. DL Barton, CL Loprinzi, SK Quella Prospective evaluation of vitamin E for hot flashes in breast cancer patients J Clin Oncol 16 1998 495 500
126. F Borrelli, E Ernst Cimicifuga racemosa: a systematic review of its clinical efficacy Eur J Clin Pharmacol 58 2002 235 241
127. G Hernandez Munoz, S Pluchino Cimicifuga racemosa for the treatment of hot flushes in women surviving breast cancer Maturitas 44 2003 14
128. S Lontos, RM Jones, PW Angus, PJ Gow Acute liver failure associated with the use of herbal preparations containing black cohosh Med J Aust 179 2003 390 391
129. A Huntley, E Ernst A systematic review of the safety of black cohosh Menopause 10 2003 58 64
130. PA Komesaroff, CV Black, V Cable, K Sudhir Effects of wild yam extract on menopausal symptoms, lipids and sex hormones in healthy menopausal women Climacteric 4 2001 144 150
131. HB Leonetti, S Longo, JN Anasti Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss Obstet Gynecol 94 1999 225 228
132. North American Menopause Society Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society Menopause 11 2004 11 33
133. Y Wyon, KMA Wijma, E Nedstrand, M Hammar A comparison of acupuncture and oral estradiol treatment of vasomotor symptoms in postmenopausal women Climacteric 7 2004 153 164
134. RR Freedman, S Woodward, B Brown, JI Javaid, GN Pandey Biochemical and thermoregulatory effecs of behavioural treatments for menopausal hot flashes Menopause 2 1995 211 218
135. JH Irvin, AD Domar, C Clark, PC Zuttermeister, R Friedman The effects of relaxation response training on menopausal symptoms J Psychosom Obstet Gynaecol 17 1996 202 207
136. L Lindh-Astrand, E Nedstrand, Y Wyon, M Hammar Vasomotor symptoms and quality of life in previously sedentary postmenopausal women randomised to physical activity or estrogen therapy Maturitas 48 2004 97 105
137. EJ Aiello, Y Yasui, SS Tworoger Effect of a yearlong, moderate-intensity exercise intervention on the occurrence and severity of menopause symptoms in postmenopausal women Menopause 11 2004 382 388
138. MG Hammond, L Hatley, LM Talbert A double blind study to evaluate the effect of methyldopa on menopausal vasomotor flushes J Clin Endocrinol Metab 58 1984 1158 1160
139. A David, R Don, G Tajchner, L Weissglas Veralipride: alternative antidopaminergic treatment for menopausal symptoms Am J Obstet Gynecol 158 1988 1107 1115
140. RM Goldberg, CL Loprinzi, JR O'Fallon Transdermal clonidine for ameliorating tamoxifen-induced hot flashes J Clin Oncol 12 1994 155 158
141. KJ Pandya, RF Raubertas, PJ Flynn Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study Ann Intern Med 132 2000 788 793
142. TB Lebherz, L French Nonhormonal treatment of the menopausal syndrome: a double-blind evaluation of an autonomic system stabilizer Obstet Gynecol 33 1969 795 799
143. Guttuso T Jr, R Kurlan, MP McDermott, K Kieburtz Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial Obstet Gynecol 101 2003 337 345
144. IM Anderson Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability J Affect Disord 58 2000 19 36
145. CL Loprinzi, JW Kugler, JA Sloan Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial Lancet 356 2000 2059 2063
146. CL Loprinzi, TM Pisansky, R Fonseca Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors J Clin Oncol 16 1998 2377 2381
147. ML Evans, E Pritts, E Vittinghoff, K McClish, KS Morgan, RB Jaffe Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial Obstet Gynecol 105 2005 161 166
148. V Stearns, KL Beebe, M Iyengar, E Dube Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial JAMA 289 2003 2827 2834
149. MA Weitzner, J Moncello, PB Jacobsen, S Minton A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer J Pain Symptom Manage 23 2002 337 345
150. V Stearns, C Isaacs, J Rowland A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer patients Ann Oncol 11 2000 17 22
151. CL Loprinzi, JA Sloan, EA Perez Phase III evaluation of fluoxetine for treatment of hot flashes J Clin Oncol 20 2002 1578 1583
152. DA Lawlor, P Juni, S Ebrahim, M Egger Systematic review of the epidemiological and trial evidence of an association between antidepressant medication and breast cancer J Clin Epidemiol 56 2003 155 163
153. V Stearns, MD Johnson, JM Rae Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine J Natl Cancer Inst 95 2003 1758 1764
154. SM Harman, EA Brinton, M Cedars KEEPS: The Kronos Early Estrogen Prevention Study Climacteric 8 2005 3 12